FGF23 and chronic kidney disease: Considering that LV hypertrophy and reduced LVEF are parameters predictive of poor cardiovascular outcome [41], and that both circulating levels of FGF23 and α-Klotho are regulated in patients with chronic kidney disease or advanced renal failure [42], alterations in the circulating levels or activity of FGF23/α-Klotho may link the chronic kidney disease with higher cardiovascular risk [43].